Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1801 - 1841 |
| Number of pages | 41 |
| Journal | Future Medicinal Chemistry |
| Volume | 5 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - 2013 |
Cite this
}
Drug discovery and human African trypanosomiasis: A disease less neglected? / Ferrins, Lori; Rahmani, Raphael Steve; Baell, Jonathan Bayldon.
In: Future Medicinal Chemistry, Vol. 5, No. 15, 2013, p. 1801 - 1841.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Drug discovery and human African trypanosomiasis: A disease less neglected?
AU - Ferrins, Lori
AU - Rahmani, Raphael Steve
AU - Baell, Jonathan Bayldon
PY - 2013
Y1 - 2013
N2 - Human African trypanosomiasis (HAT) has been neglected for a long time. The most recent drug to treat this disease, eflornithine, was approved by the US FDA in 2000. Current treatments exhibit numerous problematic side effects and are often ineffective against the debilitating CNS resident stage of the disease. Fortunately, several partnerships and initiatives have been formed over the last 20 years in an effort to eradicate HAT, along with a number of other neglected diseases. This has led to an increasing number of foundations and research institutions that are currently working on the development of new drugs for HAT and tools with which to diagnose and treat patients. New biochemical pathways as therapeutic targets are emerging, accompanied by increasing numbers of new antitrypanosomal compound classes. The future looks promising that this collaborative approach will facilitate eagerly awaited breakthroughs in the treatment of HAT.
AB - Human African trypanosomiasis (HAT) has been neglected for a long time. The most recent drug to treat this disease, eflornithine, was approved by the US FDA in 2000. Current treatments exhibit numerous problematic side effects and are often ineffective against the debilitating CNS resident stage of the disease. Fortunately, several partnerships and initiatives have been formed over the last 20 years in an effort to eradicate HAT, along with a number of other neglected diseases. This has led to an increasing number of foundations and research institutions that are currently working on the development of new drugs for HAT and tools with which to diagnose and treat patients. New biochemical pathways as therapeutic targets are emerging, accompanied by increasing numbers of new antitrypanosomal compound classes. The future looks promising that this collaborative approach will facilitate eagerly awaited breakthroughs in the treatment of HAT.
UR - http://www.future-science.com/doi/abs/10.4155/fmc.13.162
U2 - 10.4155/fmc.13.162
DO - 10.4155/fmc.13.162
M3 - Article
VL - 5
SP - 1801
EP - 1841
JO - Future Medicinal Chemistry
JF - Future Medicinal Chemistry
SN - 1756-8919
IS - 15
ER -